Next Article in Journal
Health and Lifestyle of Patients with Mesothelioma: Protocol for the Help-Meso Study
Previous Article in Journal
Epidemiological Characteristics of COVID-19 Inpatient Deaths during the First and Second Waves in Limpopo Province, South Africa
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoR
Volume 2
Issue 3
10.3390/jor2030010
jor-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Use of Mepolizumab in Children and Adolescents with Asthma in the USA

by
Jaclyn Davis
1,
Pamela M. McMahon
2,
Emily Welch
2,
Cheryl McMahill-Walraven
3,
Aziza Jamal-Allial
4,
Tancy Zhang
2,
Christine Draper
2,
Anne Marie Kline
3,
Leslie Koerner
4,
Jeffrey S. Brown
2,
Melissa Van Dyke
5 and
Ann Chen Wu
1,2,*
1
Pulmonary Division, Boston Children’s Hospital, Boston, MA 02115, USA
2
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02115, USA
3
Healthagen, Part of the CVS Health Family of Companies, Blue Bell, PA 19422, USA
4
HealthCore, Inc., Wilmington, DE 19801, USA
5
Respiratory Epidemiology Therapy Area, GlaxoSmithKline, Collegeville, PA 19426, USA
*
Author to whom correspondence should be addressed.
J. Respir. 2022, 2(3), 123-128; https://doi.org/10.3390/jor2030010
Submission received: 25 May 2022 / Revised: 12 July 2022 / Accepted: 13 July 2022 / Published: 19 July 2022
Browse Figure
Review Reports Versions Notes

Abstract

Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease. Biologics are the newest class of anti-asthma therapy approved for use in patients with severe asthma > 6 years with the eosinophilic phenotype. Objective: The goals of this study were to (1) describe the baseline characteristics of new US pediatric mepolizumab users between 2015 and end dates that varied by data partner (6/30/19–5/31/21), (2) describe asthma medication use in the 12 months preceding and following mepolizumab initiation in this group and (3) assess adherence and persistence to mepolizumab in the 12 months following initiation. Methods: Through an observational cohort study using insurance claim databases, we studied children with a diagnosis of asthma in the preceding 12 months who started mepolizumab and had 12 months of follow-up data. Results: Baseline characteristics of the 72 children who initiated mepolizumab showed variable comorbidities, the most common being allergic rhinitis (88%) and recurrent respiratory infections (71%), as well as varied medication dispensings and patterns of healthcare utilization prior to initiating mepolizumab. Half met the criteria for severe asthma per the GINA guidelines. Comparing weighted averages of treatments dispensed in the 12 months prior to versus following mepolizumab initiation, we observed no significant change in asthma treatments dispensed. Conclusion: This study demonstrates that pediatric patients prescribed mepolizumab have variable previous treatment history and severity of disease, and we found no evidence that mepolizumab alters other asthma medications dispensed in the first 12 months following initiation.
Keywords: asthma; pediatric; mepolizumab; biologics asthma; pediatric; mepolizumab; biologics

Share and Cite

MDPI and ACS Style

Davis, J.; McMahon, P.M.; Welch, E.; McMahill-Walraven, C.; Jamal-Allial, A.; Zhang, T.; Draper, C.; Kline, A.M.; Koerner, L.; Brown, J.S.; et al. Use of Mepolizumab in Children and Adolescents with Asthma in the USA. J. Respir. 2022, 2, 123-128. https://doi.org/10.3390/jor2030010

AMA Style

Davis J, McMahon PM, Welch E, McMahill-Walraven C, Jamal-Allial A, Zhang T, Draper C, Kline AM, Koerner L, Brown JS, et al. Use of Mepolizumab in Children and Adolescents with Asthma in the USA. Journal of Respiration. 2022; 2(3):123-128. https://doi.org/10.3390/jor2030010

Chicago/Turabian Style

Davis, Jaclyn, Pamela M. McMahon, Emily Welch, Cheryl McMahill-Walraven, Aziza Jamal-Allial, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S. Brown, and et al. 2022. "Use of Mepolizumab in Children and Adolescents with Asthma in the USA" Journal of Respiration 2, no. 3: 123-128. https://doi.org/10.3390/jor2030010

APA Style

Davis, J., McMahon, P. M., Welch, E., McMahill-Walraven, C., Jamal-Allial, A., Zhang, T., Draper, C., Kline, A. M., Koerner, L., Brown, J. S., Van Dyke, M., & Wu, A. C. (2022). Use of Mepolizumab in Children and Adolescents with Asthma in the USA. Journal of Respiration, 2(3), 123-128. https://doi.org/10.3390/jor2030010

Article Metrics

Back to TopTop